Patient identifier = (b)(6).This report is being filed on an international product, list number 8l44 that has a similar product distributed in the us, list number 6l22.The complaint investigation for (b)(6) results for one sample tested with the architect anti-hbc ii assay included a review of data and information provided by the customer, search for similar complaints, ticket trending review, labeling review, device history record review and inhouse testing of retained kits with the complaint lot number.Trending review determined no trends for the issue for the product.Return testing was not completed as returns were not available.Sensitivity testing was performed with a retained kit of lot 05302be01 and determined that the sensitivity performance is not negatively impacted.Device history record review did not identify any non-conformances or deviations with the lot for the complaint issue.A review of the product labeling concluded that the issue is sufficiently addressed.Based on the investigation no product deficiency was identified for the architect anti-hbc ii assay, lot 05302be01.
|